Surge is a biotech company focused on optimizing treatment for patients undergoing surgery. Our multidisciplinary team has developed a test to identify patients at risk for complications. By anticipating surgical risks to enable personalization of the care pathway, this innovation will revolutionize the patient experience and shift the standard of surgical care. Our team shares a common vision for healthcare innovation: to develop patient-focused solutions that benefit the entire healthcare system.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/22/22 | $2,600,000 | Pre-Seed |
Boutique Venture Partners HCVC Nicolas Godin | undisclosed |
